Overview

Dose-finding of Semaglutide Administered Subcutaneously Once Daily Versus Placebo and Liraglutide in Subjects With Type 2 Diabetes

Status:
Completed

Trial end date:
2016-10-13

Target enrollment:

Participant gender:

Summary

This trial is conducted globally. The aim of this trial is to investigate dose-finding of semaglutide administered subcutaneously once daily versus placebo and liraglutide in subjects with type 2 diabetes

Phase:

Phase 2

Details

Lead Sponsor:

Novo Nordisk A/S

Treatments:

Liraglutide